Charles River Laboratories Intl. (NYSE:CRL) had its price objective upped by equities researchers at JPMorgan Chase & Co. from $110.00 to $120.00 in a note issued to investors on Wednesday. The firm presently has an “overweight” rating on the medical research company’s stock. JPMorgan Chase & Co.’s target price would indicate a potential upside of 11.46% from the stock’s current price.

CRL has been the topic of a number of other research reports. Robert W. Baird set a $117.00 target price on shares of Charles River Laboratories Intl. and gave the company a “buy” rating in a research note on Monday, November 13th. Zacks Investment Research upgraded shares of Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $129.00 target price on the stock in a research note on Tuesday, October 24th. Evercore ISI assumed coverage on shares of Charles River Laboratories Intl. in a research note on Thursday, January 18th. They set an “in-line” rating and a $117.00 target price on the stock. SunTrust Banks cut shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating and boosted their price target for the stock from $107.89 to $111.00 in a research note on Monday, January 22nd. They noted that the move was a valuation call. Finally, Bank of America decreased their price target on shares of Charles River Laboratories Intl. from $117.00 to $115.00 and set a “buy” rating on the stock in a research note on Friday, November 10th. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $113.62.

Charles River Laboratories Intl. (NYSE CRL) opened at $107.66 on Wednesday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.62 and a current ratio of 1.88. Charles River Laboratories Intl. has a one year low of $85.00 and a one year high of $119.05. The firm has a market cap of $4,830.40, a price-to-earnings ratio of 26.26, a P/E/G ratio of 1.50 and a beta of 0.74.

Charles River Laboratories Intl. (NYSE:CRL) last released its earnings results on Tuesday, February 13th. The medical research company reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $1.25 by $0.15. Charles River Laboratories Intl. had a net margin of 10.72% and a return on equity of 26.58%. The company had revenue of $478.50 million for the quarter, compared to analysts’ expectations of $475.02 million. During the same quarter in the previous year, the company earned $1.21 EPS. Charles River Laboratories Intl.’s revenue for the quarter was up 2.5% on a year-over-year basis. research analysts expect that Charles River Laboratories Intl. will post 5.14 earnings per share for the current year.

In other Charles River Laboratories Intl. news, Director Online Communications Bdirect sold 131,000 shares of the business’s stock in a transaction on Thursday, January 18th. The shares were sold at an average price of $0.29, for a total value of $37,990.00. Also, Director C Richard Reese sold 10,227 shares of the business’s stock in a transaction on Wednesday, December 6th. The stock was sold at an average price of $102.40, for a total transaction of $1,047,244.80. Following the completion of the sale, the director now owns 51,444 shares in the company, valued at approximately $5,267,865.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 195,673 shares of company stock worth $2,644,046. Corporate insiders own 2.20% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in CRL. Stifel Financial Corp purchased a new stake in shares of Charles River Laboratories Intl. during the 2nd quarter valued at about $261,000. State Street Corp raised its position in shares of Charles River Laboratories Intl. by 2.3% during the 2nd quarter. State Street Corp now owns 1,268,308 shares of the medical research company’s stock valued at $128,288,000 after buying an additional 28,365 shares in the last quarter. Cubist Systematic Strategies LLC raised its position in shares of Charles River Laboratories Intl. by 83.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 6,272 shares of the medical research company’s stock valued at $634,000 after buying an additional 2,845 shares in the last quarter. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Charles River Laboratories Intl. during the 2nd quarter valued at about $344,000. Finally, The Manufacturers Life Insurance Company raised its position in shares of Charles River Laboratories Intl. by 2.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 69,954 shares of the medical research company’s stock valued at $7,076,000 after buying an additional 1,505 shares in the last quarter. Hedge funds and other institutional investors own 97.13% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “JPMorgan Chase & Co. Raises Charles River Laboratories Intl. (CRL) Price Target to $120.00” was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://theolympiareport.com/2018/02/14/jpmorgan-chase-co-raises-charles-river-laboratories-intl-crl-price-target-to-120-00.html.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Analyst Recommendations for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.